OC
IMRX icon

Oppenheimer & Co’s Immuneering IMRX Stock Holding History

Oppenheimer & Co’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$175K Buy
35,000
+1,000
+3% +$5.06K ﹤0.01% 1674
2026
Q1 		$179K Buy
+34,000
New +$174K ﹤0.01% 1593

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Oppenheimer & Co's IMRX Position: Q2 2026 in Review

Oppenheimer & Co increased its Immuneering (IMRX) stake by 2.9% in Q2 2026, buying an estimated $5.06K and bringing the position to 35,000 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

Oppenheimer & Co first reported a position in IMRX in Q1 2026 and has held it in 2 quarters since. The position peaked at $179K in Q1 2026. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Oppenheimer & Co held 35,000 shares of Immuneering worth $175K as of Q2 2026.
  • Oppenheimer & Co bought 1,000 Immuneering shares in Q2 2026, an estimated $5.06K.
  • Immuneering made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1674 holding.
  • Oppenheimer & Co first reported a position in Immuneering in Q1 2026 and has held it in 2 quarters since.
  • Oppenheimer & Co's Immuneering position peaked at $179K in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.